Anesiva Defines Regulatory Pathway for Adle... (essary for sensory or motorsensations an...)

Anesiva Defines Regulatory Pathway for Adlea with FDA

Date:10/10/2007

essary for sensory or motor sensations and proprioception.

Pharmacokinetic studies of Adlea showed that when it is locally administered to the site of pain, there appears to be limited systemic exposure. Its short duration of systemic exposure (hours) relative to the long duration of analgesia (weeks to months) resulting from a single treatment of Adlea is particularly important in this typically elderly and vulnerable patient population and may also potentially offer a safer treatment option in the management of chronic osteoarthritis pain. Importantly, the prolonged analgesic effect resulting from a single or stepped dose, localized administration of Adlea does not seem to be associated with the systemic side effects commonly associated with NSAIDs (gastrointestinal and renal toxicities, and impaired clotting), COX-2 inhibitors (cardiovascular risks and renal toxicity), or opiates (respiratory depression, nausea/vomiting, sedation, disorientation, physical dependence, and the risk of addiction). In clinical studies to date, Adlea has been shown to be well tolerated.

About Bunionectomy Surgeries

A bunionectomy is a surgical procedure to align the bones of the big toe joint thereby excising the bunion. A bunion is an enlargement of the joint at the base of the big toe caused by the misalignment of the big toe joint. It is usually a result of inflammation and irritation from poorly fitting (narrow and tight) shoes and is a condition that can be exacerbated by excessive standing or running. Bunionectomies are often performed as out-patient procedures enabling patients to go home the same day of their surgery.

About Anesiva and its Diverse Portfolio of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal in
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
3. Stanford Researchers Find Brain Pathway of Depression in Rats
4. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
5. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
6. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
7. Researchers Identify Intracellular Pathway of Alfacells Onconase

Post Your Comments:

(Date:12/14/2009)... Tenn., Dec. 14 Embarrassing and sometimes uncomfortable ... National researchers are taking note of a new ... approval process. The Knoxville-based company, EDP Biotech ... revolutionary, ColoMarker, an affordable medical device doctors can use ... sample. "When you consider that 30% of colon ...

(Date:12/14/2009)... Calif., Dec. 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ... its New Drug Application (NDA) for Staccato® loxapine (AZ-004) ... AZ-004 is an inhalation product candidate being developed for ... or bipolar disorder. The IND for Staccato ... 2005. ,, "AZ-004 has delivered a predictable and consistent ...

(Date:12/14/2009)... 14 Corgenix Medical Corporation (OTC ... marketer of diagnostic test kits, and BG ... sciences company, announced today a supply agreement ... products in enzyme-linked immunosorbent assay (ELISA) microtiter ... is seeking regulatory clearance in the United ...

Breaking Medicine Technology:EDP Biotech Takes Next Step in the Development of ColoMarker 2 EDP Biotech Takes Next Step in the Development of ColoMarker 3 Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2 Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3 Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4 Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5 Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6 Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2 Drug ads ineffective for boosting sales could cost taxpayers 3A UBC Harvard study 61994 1 Drug ads ineffective for boosting sales could cost taxpayers 3A UBC Harvard study 61994 2 The cause behind the characteristic shape of a long leaf revealed 10881 1 The cause behind the characteristic shape of a long leaf revealed 10881 2 Water droplets direct self assembly process in thin film materials 14949 1 Water droplets direct self assembly process in thin film materials 14949 2

[0] EDP Biotech Takes Next Step in the Development of ColoMarker [0] Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA [0] Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)

... SAN FRANCISCO, Oct. 26 Semafore Pharmaceuticals Inc.,announced ... at the 2007,AACR-NCI- EORTC International Conference in San ... synergistic effects,with certain standard chemotherapy agents in vitro ... showed significant (p<0.001) synergistic growth,inhibition of prostate cancer ...

... 25 Paratek Pharmaceuticals, Inc. announced,today that ... a $40 million private,financing. Aisling Capital led ... D.E. Shaw and Boston Life Science Venture ... BioVentures, BioFund,Ventures, HBM BioVentures, Lombard Odier Darier ...

Other Medicine Technology:Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents 2 Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections 2 Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections 3 Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections 4

Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections

(Date:12/14/2009)... ,, NEW YORK, Dec. 14 /PRNewswire-USNewswire/ ... study (MTF) -- the largest survey on teen drug ... -- underscores that teens, intentional abuse of prescription (Rx) ... for concern, with an alarming number of young people ... ,, Teen Abuse of Medication Continues to ...

(Date:12/14/2009)... 14 The Hemophilia Federation of America ... issues involving the Teamsters Local 929 and the ... national blood system depends on skilled workers to ... is distilled into products such as clotting factor ... disease. ,, The Division of Blood Services ...

(Date:12/14/2009)... Exercise benefited men whose disease had been treated, hadn,t ... -- Exercise appears to reduce the risk of death ... study, which began in January 1986, included 668 men ... stage III colon cancer that had not spread (nonmetastatic ... that asked them about any new cancer and disease ...

(Date:12/14/2009)... protection, study finds, , , MONDAY, Dec. 14 (HealthDay News) ... their morning without a cup or two of java: ... developing type 2 diabetes. , That,s the conclusion ... coffee you drink, the lower your risk of diabetes. ... percent reduction in the risk of diabetes, the researchers ...

(Date:12/14/2009)... are underdiagnosed, poorly treated and highly stigmatized, according ... H. Rubin, M.D., Ph.D. So these Washington University ... problems. , In "Demystifying Psychiatry," Zorumski and Rubin, ... treating psychiatric patients and helping patient families, say ... and treatment result from a lack of understanding ...

Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2 Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3 Health News:HFA Voices Blood Safety Concerns 2 Health News:Physical Activity May Prolong Survival After Colon Cancer 2 Health News:Coffee, Tea Might Stave Off Diabetes 2 Health News:Coffee, Tea Might Stave Off Diabetes 3 Health News:Book demystifies psychiatry for the general public 2 Health News:Book demystifies psychiatry for the general public 3

[0] Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results [0] HFA Voices Blood Safety Concerns [0] Physical Activity May Prolong Survival After Colon Cancer [0] Coffee, Tea Might Stave Off Diabetes [0] Book demystifies psychiatry for the general public

... Environmentalists want bisphenol A banned from products for infants ... organizations in the United States and Canada are calling ... bisphenol A (BPA) in baby bottles, toddler sippy cups, ... "This is quite concerning. All 19 polycarbonate bottles [investigated ...

... be getting an,unfair rap for disrupting women,s sleep at ... increase during the,transition into menopause, reinforcing the idea that ... in sleep laboratories, the,connection between hot flashes and sleep ... Women,s Health Watch., A new study concludes that ...

... -- A new study by researchers at Northwestern University,s ... how best to treat patients in respiratory distress in ... believed that high levels of carbon dioxide (CO2) or ... acute lung disease may be beneficial to them. Now, ...

... LAS VEGAS, Feb. 7 American Pacific,Corporation (Nasdaq: ... quarter ended December 31, 2007., We provide non-GAAP ... A reconciliation of the non-GAAP measures to the most ... data., FINANCIAL HIGHLIGHTS, Quarter Ended December 31, ...

... episode, OAKLAND, Calif., Feb. 7 Nytera Tilmon ... care for her seven children,all of whom live with ... a new television show revealing Nytera,s story and others,behind ... is,called "Union Time" and it,s the only national labor-produced ...

... After just seven months in print, Cell Stem Cell, ... New Journal - Science, Technology & Medicine, by the Professional ... Publishers (AAP). , This honor, which is among the Association ... a year after Cell Stem Cell published its first issue ...

Report Shows Dangerous Chemical Can Leach From Baby Bottles Hot Flashes Not Always to Blame for Sleep Problems in Menopausal Women, Reports the Harvard Women's Health Watch Study suggests new therapy for lung disease patients American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter Healthcare Crisis Brought to Life in New TV Show Cell Stem Cell named 'Best New Journal' of 2007

CVC 223 is an assayed quality control material used for confirming the calibration and linearity of CO-Oximeter instrumentation....

... assayed quality control material used for monitoring the ... It is for specific use on Bayer analyzers ... 288, and 270) and the AVOX Systems CO-Oximeters ... used on the IRMA TRUpoint®. CC 527 is ...

... QC 623 is an assayed quality control material ... available in four (4) levels for monitoring analyzer ... It may be used on multiple test analyzers ... the Radiometer 600). QC623 is also for use ...

Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....

Medicine Products:

CVC 223 CO-Oximeter Calibration Verification Controls CC 527 Blood Gas, Electrolyte, CO-Oximeter (Bayer® and AVOX Systems®) Control QC 623 Blood Gas, Electrolyte Control Equinox Cosmetic Enhancement Contact Lens

Anesiva Defines Regulatory Pathway for Adle...(essary for sensory or motorsensations an...),Health